日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study

贝鲁莫舒地尔作为二线或后续治疗方案治疗激素依赖性/耐药性慢性移植物抗宿主病（cGVHD）的长期随访：一项日本研究的临床结果

期刊:Bone Marrow Transplantation
影响因子:5.2
doi:10.1038/s41409-025-02775-z
Kato, Koji; Inamoto, Yoshihiro; Kawakita, Toshiro; Onishi, Yasushi; Matsuoka, Ken-Ichi; Shiratori, Soichi; Ikegame, Kazuhiro; Hiramoto, Nobuhiro; Toyosaki, Masako; Katayama, Yuta; Koga, Yuhki; Murayama, Shun; Sasagawa, Yuji; Shindo, Mami; Teshima, Takanori; Hatake, Kiyohiko; Maeda, Yoshinobu
免疫/内分泌
发表日期：2026
文献求助 收藏

Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph+ ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan

在日本开展的一项上市后监测研究，旨在评估帕纳替尼治疗724例慢性粒细胞白血病（CML）和Ph+急性淋巴细胞白血病（ALL）患者的真实世界疗效，尤其关注动脉闭塞事件。

期刊:Japanese Journal of Clinical Oncology
影响因子:2.2
doi:10.1093/jjco/hyae061
Takahashi, Naoto; Kondo, Takeshi; Ikari, Yuji; Fukumoto, Yoshihiro; Hatake, Kiyohiko; Masunari, Akira; Nishibayashi, Seiji; Kageyama, Akiko; Fukuta, Yasuhiko; Tojo, Arinobu
白血病
细胞生物学
粒细胞
发表日期：2024
文献求助 收藏

Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan

日本对纳武利尤单抗治疗经典型霍奇金淋巴瘤的上市后安全性和有效性进行监测

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-024-03734-y
Kawasaki, Akira; Hatake, Kiyohiko; Matsumura, Itaru; Izutsu, Koji; Hoshino, Tomohiro; Akamatsu, Ayumi; Kakuuchi, Akito; Tobinai, Kensei
淋巴瘤
发表日期：2024
文献求助 收藏

Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study

copanlisib治疗日本复发/难治性惰性非霍奇金淋巴瘤患者的安全性和抗肿瘤活性：一项Ib/II期研究

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-022-03455-0
Fukuhara, Noriko; Maruyama, Dai; Hatake, Kiyohiko; Nagai, Hirokazu; Makita, Shinichi; Kamezaki, Kenjiro; Uchida, Toshiki; Kusumoto, Shigeru; Kuroda, Junya; Iriyama, Chisako; Yanada, Masamitsu; Tsukamoto, Norifumi; Suehiro, Youko; Minami, Hironobu; Garcia-Vargas, Jose; Childs, Barrett H; Yasuda, Masanobu; Masuda, Shigeo; Tsujino, Toshiaki; Terao, Yui; Tobinai, Kensei
肿瘤
淋巴瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

一项针对日本复发或难治性大B细胞淋巴瘤患者的axicabtagene ciloleucel II期研究

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-021-02033-4
Kato, Koji; Makita, Shinichi; Goto, Hideki; Kanda, Junya; Fujii, Nobuharu; Shimada, Kazuyuki; Akashi, Koichi; Izutsu, Koji; Teshima, Takanori; Fukuda, Natsuko; Sumitani, Tokuhito; Sumi, Hiroyuki; Shimizu, Shinji; Kakurai, Yasuyuki; Yoshikawa, Kenji; Tobinai, Kensei; Usui, Noriko; Hatake, Kiyohiko
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2022
文献求助 收藏

Phase I, multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies

一项针对日本成年晚期恶性肿瘤患者的阿伐多米特I期多中心剂量递增研究

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.14704
Hatake, Kiyohiko; Chou, Takaaki; Doi, Toshihiko; Terui, Yasuhito; Kato, Harumi; Hirose, Takayuki; Seo, Sachiko; Pourdehnad, Michael; Ogaki, Yumi; Fujimoto, Hiroshi; Hagner, Patrick R; Yamamoto, Kazuhito
肿瘤
肿瘤免疫
发表日期：2021
文献求助 收藏

Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

非霍奇金B细胞淋巴瘤患者粒细胞集落刺激因子制剂最佳选择因素及R-CHOP剂量减少/延迟的预测因素（NHL 2亚组分析）

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-021-08068-0
Yokoyama, Masahiro; Kusano, Yoshiharu; Inoue, Norihito; Nishimura, Noriko; Mishima, Yuko; Nukada, Tomoyuki; Hatake, Kiyohiko; Terui, Yasuhito
B细胞
HOP
淋巴瘤
CHOP
粒细胞
细胞生物学
免疫/内分泌
发表日期：2021
文献求助 收藏

Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study

在日本复发/难治性B细胞非霍奇金淋巴瘤患者中，polatuzumab vedotin的安全性和药代动力学：一项1期剂量递增研究

期刊:Japanese Journal of Clinical Oncology
影响因子:2.2
doi:10.1093/jjco/hyaa169
Kinoshita, Tomohiro; Hatake, Kiyohiko; Yamamoto, Kazuhito; Higuchi, Yusuke; Murakami, Satsuki; Terui, Yasuhito; Yokoyama, Masahiro; Maruyama, Dai; Makita, Shinichi; Hida, Yukari; Saito, Tomohisa; Tobinai, Kensei
B细胞
细胞生物学
淋巴瘤
免疫/内分泌
发表日期：2021
文献求助 收藏

Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

布伦妥昔单抗治疗日本复发/难治性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者的安全性：一项上市后监测研究

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-020-03039-w
Izutsu, Koji; Ogura, Michinori; Tobinai, Kensei; Hatake, Kiyohiko; Sakamoto, Shigeru; Nishimura, Masanori; Hoshino, Miyako
细胞生物学
淋巴瘤
发表日期：2021
文献求助 收藏

Correction to: Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

更正：布伦妥昔单抗治疗日本复发/难治性霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤患者的安全性概况：一项上市后监测研究

期刊:International Journal of Hematology
影响因子:1.8
doi:10.1007/s12185-021-03091-0
Izutsu, Koji; Ogura, Michinori; Tobinai, Kensei; Hatake, Kiyohiko; Sakamoto, Shigeru; Nishimura, Masanori; Hoshino, Miyako
细胞生物学
淋巴瘤
发表日期：2021
文献求助 收藏